Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Amarin Pharma, Inc. et al v. Hikma Pharmaceuticals USA Inc., et al.
Case Number:
1:20-cv-01630
Court:
Nature of Suit:
Judge:
Firms
Companies
- Association for Accessible Medicines
- Health Net Inc.
- Hikma Pharmaceuticals PLC
- Mochida Pharmaceutical Co. Ltd.
Sectors & Industries:
-
January 06, 2022
Generics Catch A Break With Hikma's Skinny Label Win
Generic-drug makers have spent more than a year voicing concerns that the Federal Circuit's holding in GlaxoSmithKline v. Teva threatened their ability to sell generic drugs that leave patent-protected indications off the label, but a Delaware federal judge this week quelled some of those fears by quickly throwing out a challenge to such "skinny labels."
-
January 04, 2022
Hikma Beats Amarin's 'Skinny Label' Patent Suit
Hikma Pharmaceuticals USA Inc.'s generic heart drug does not infringe three patents underlying Amarin Pharma Inc.'s drug Vascepa, a Delaware federal judge ruled Tuesday, breaking with the recommendation from a magistrate judge.
-
August 20, 2021
Generics Group Says 'Skinny Label' Suit Should Not Proceed
The Association for Accessible Medicines has urged a Delaware federal judge to reject part of a magistrate judge's report and recommendation not to dismiss Amarin Pharma Inc.'s infringement suit against Hikma Pharmaceuticals USA Inc. over its heart drug Vascepa, saying that if the suit goes forward, patients will be forced to pay higher prices for branded drugs.
-
August 03, 2021
Hikma Should Face Amarin's Patent Suit, Magistrate Says
Hikma Pharmaceuticals should not be able to dodge a lawsuit claiming it encouraged doctors to prescribe its generic version of the heart drug Vascepa for uses covered by a series of Amarin patents, a Delaware federal magistrate judge says.